Contact | Site Index   
Visit Medtronic.com

Introducing the
Endeavor Zotarolimus-Eluting Coronary Stent System

Efficacy Proven. Safety Delivered.

With more than 10,000 patients enrolled and patient follow-up of up to four years,* the Endeavor stent has:

• Superior reduction in TLR vs. BMS. ¹
• Excellent early and late safety profile. ²
• Low periprocedural NQWMI and proven Driver® stent platform. ³
• Extremely low rate of cardiac death, MI and stent thrombosis. ⁴

Endeavor offers more from a drug-eluting stent -

TLR reduction of a DES...
without compromising long-term safety

 

*EI, E II, E II CA, E III, E IV, E-FIVE, E pk (n=10,518). (Note: E-FIVE enrolled, E pk, 9 months; E IV, 12 months; E II CA and E III, 2 years, E II 3 years, E I 4 years)
¹ENDEAVOR II clinical trial—Endeavor: n = 598, Driver: n = 599.
²Endeavor: E I, E II, E II CA, E III, E IV, E pk (n = 2132). (Note: E pk, 9 months; E IV, 12 months; E II CA and E III, 2 years) Driver: E II (n = 596).
²NQWMI: ENDEAVOR III—0.6%; ENDEAVOR IV—0.5%.
²Endeavor: E I, E II, E II CA, E III, E IV, E pk (n = 2132). (Note: E pk, 9 months; E IV, 12 months; E II CA and E III, 2 years); Cardiac death—1.0%; MI—2.7%; Stent thrombosis (protocol)—0.5%.